Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes.
Latagliata
R
R
Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. rob.lati@libero.it
Oliva
E N
EN
Volpicelli
P
P
Carmosino
I
I
Breccia
M
M
Vincelli
I
I
Alati
C
C
Napoleone
L
L
Vozella
F
F
Nobile
F
F
Alimena
G
G
D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000188:drug therapy*; D020732:Cytogenetic Analysis; D004921:Erythropoietin / Q000008:administration & dosage* / Q000633:toxicity; D005260:Female; D006454:Hemoglobins; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000188:drug therapy; D011994:Recombinant Proteins; D016896:Treatment Outcome
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin